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The Middle East and North Africa (MENA) region suﬀers a drastic change from a traditional diet to an industrialized diet. This
has led to an unparalleled increase in the prevalence of chronic diseases. This review discusses the role of nutritional genomics,
or the dietary signature, in these dietary and disease changes in the MENA. The diet-genetics-disease relation is discussed in
detail. Selected disease categories in the MENA are discussed starting with a review of their epidemiology in the diﬀerent MENA
countries,followedbyanexaminationoftheknowngeneticfactorsthathavebeenreportedinthediseasediscussed,whetherinside
or outside the MENA. Several diet-genetics-disease relationships in the MENA may be contributing to the increased prevalence
of civilization disorders of metabolism and micronutrient deﬁciencies. Future research in the ﬁeld of nutritional genomics in the
MENA is needed to better deﬁne these relationships.
1.Introduction
Over the past few decades, the MENA has been witnessing
signiﬁcant changes in food habits paralleled by an important
preponderance of metabolite-related diseases. In a region
whose traditional diet is known to be healthy due to
high vegetable proteins, ﬁbers, minerals, and vitamins with
low content of unfavorable food products, the “industri-
alization/westernization of the diet” is a well-studied and
documentedphenomenon[1–3].TheMEN Ahasbeenlosing
its traditional diet which was distinguished by its diversity
and richness in raw foods, proteins, and multivitamins,
in the favor of a more industrial diet which consists of
increased preprocessed foods, sugars, fats, alcohol, animal
products, saturated- and trans-fatty acids, and relatively
less vitamins and minerals with decreased consumption of
milk, fruits, and vegetables [4]. A big part of this change
is attributed to the lifestyle changes and globalization with
the invasion of western fast food to the MENA countries.
Dietary choices, minimum physical activity, religious habits,
consumer ignorance, high population growth rates, eco-
nomic factors, and lack of both protection laws and food
fortiﬁcationprograms areothercritical factorsthatinﬂuence
the nutritional status in the region [5]. These changes in
dietary and lifestyle patterns contribute to an increase in
the rates of micronutrients deﬁciencies, diet-related chronic
diseases, and obesity in all groups of the population in the
region [5]. Due to this grave impact on chronic diseases,
diet became a target of public health initiatives that aim at
restoring the traditional diet of MENA countries in order to
improve health conditions in their populations [6–8]. The
epidemiology of diet-related diseases in the MENA region
and background information on the diet-genetics-disease
interaction, followed by nutrigenomic examples on diet-
related diseases in the MENA region, will be discussed for
the ﬁrst time in this paper.
2.Epidemiology of Diet-Related
Diseasesinthe MENA
We review the numbers and trends for selected chronic
metabolic diseases and micronutrient deﬁciencies in the
diﬀerent countries of the MENA where data are available2 J o u r n a lo fN u t r i t i o na n dM e t a b o l i s m
(Figure 1). Given the lack of nationwide data, prevalence
rates are commonly reported as estimations [9, 10]. Since
1982, the need for “direct evidence of a secular [increase]”
in diseases has been established, prospecting an association
with “acculturation” of traditional or rural populations [11].
Still, the numbers show alarming trends for cardiovascular
diseases and metabolic disorders, namely, insulin resis-
tance,adiposity,dyslipidemias,andatherosclerosis.Likewise,
micronutrient deﬁciencies (MNDs) have been heavily stud-
ied recently due to their crucial contribution to the global
burden of many chronic diseases.
The region is witnessing an “explosion” of Type 2 Dia-
betes Mellitus (T2DM) according to the International Dia-
betes Foundation (IDF) (Figure 2(a)) with ﬁve countries of
the MENA ranking among the top ten diabetic worldwide
[15]. Similarly, the IDF reports an increase in the incidence
of Type 1 DM in children of the MENA over the past decade
(Figure 2(b)). The World Health Statistics of the WHO show
a sharp rise in the prevalence of obesity (Figure 3), which is
the most powerful and easily reported risk marker and hence
the sole epidemiological WHO indicator for cardiovascular
and metabolic comorbidities. In one epidemiological study,
cardiovascular mortality in the MENA has been estimated
to triple from 1990 to 2020 (Figure 4). Table 1 summarizes
rates of cardiovascular diseases and two major comorbid risk
factors,hypertensionandthemetabolicsyndrome,withwide
variations across countries of the MENA.
In the other category of diseases, deﬁciencies in vitamins
and minerals aﬀect particularly children and women of
childbearing age. MNDs impair physical and mental devel-
opment of children, exacerbate infections and chronic dis-
eases, and impact morbidity and mortality. Most countries
of the MENA have widespread MNDs, yet countries of the
Gulf Cooperation Council, Iran, and Tunisia have moderate
levels of MNDs [20]. Among MNDs, iron deﬁciency is the
most prevalent nutritional problem in the MENA [21]. Its
prevalence in the region varies from 17 to 70% among
preschoolers, 14 to 42% among adolescents, and 11 to more
than 40% among women of childbearing age. Severe iron
deﬁciency is a direct cause of anemia. Nonnutritional genetic
anemias are known to be relatively common in the region
but will not be tackled because they are not aﬀected by
dietary factors. Nutritional deﬁciencies other than iron, such
as folic acid, vitamin B12, and vitamin C, are also prevalent
in some countries of the region but data are scarce [20]. The
Middle Eastern and South Asian regions have the highest
rates of Vitamin D Deﬁciency (VDD) worldwide [22]. The
prevalence ranges of VDD in the MENA are 46–83% for
adolescents and adults, and 50–62% among veiled women
[5]. It reaches up to 70% in Iran [23] and 80% in Saudi
Arabia [24]. Table 2 shows prevalence of VDD and iron
deﬁciencyincountriesoftheMENAwheredataareavailable.
3. The DietarySignatureon the Genome
The eﬀect of food on gene function is the focus of nutritional
genomics, an emerging ﬁeld of study that focuses on the
molecular, cellular, and systemic levels of this eﬀect [25, 26].
The abundance of calories, macro- and micronutrients,
and bioactive food elements constitutes the nutritional
environment that alters the genome, the epigenome, the
posttranscriptional regulation, and the posttranslational
modiﬁcations, leading to a variety of metabolic functional
gene-products, as shown in Figure 5. The nutritional envi-
ronment channels the function of gene-products into cer-
tain pathways, preferring certain biological activities over
others and resulting in the ﬁnal phenotypic outcome and
health-disease status. Correspondingly, two disciplines of
nutritional genomics are entertained: nutrigenomics and
nutrigenetics. The former started as a focus on the eﬀect of
nutrients on gene expression, while the latter, yet a diﬀerent
ﬁeld of study, emerged in search of approaches to alter
the clinical manifestations of certain rare diseases, such as
certain inborn errors of metabolism, via personalized diet.
The link between them is the functional gene product. It
is the end-point in nutrigenomics and the starting point in
nutrigenetics. Other conventional terminologies relevant to
the diet-genetics-disease relation will also be treated in the
following section, prior to discussion of the dietary signature
on the genome in the MENA.
(1) The genome sequence of DNA base pairs dictates
the primary genetic proﬁle and hence gene function. DNA
sequence variants—gene variants and single nucleotide
polymorphisms (SNPs)—designate an alteration of gene
structure with or without functional changes that might
or might not lead to a complex gene-function relationship
depicted in diﬀerent diseases [27]. The epigenome, an
emerging concept in genetic research, is a set of nongenetic
factors, such as diet, that change the expressed gene outcome
without aﬀecting the structure of the DNA per se.
(2) Nutrigenomics considers environmental factors of
alimentary source that may disrupt the DNA sequence in
peptide-coding and in promoter regions, aﬀecting the gene
product. Other environmental nutrigenomic factors include
abundance of macro and micronutrient components of the
diet, presence of other bioactive food elements, and caloric
content. Under- or overnutrition in the maternal environ-
mentsetsepigeneticprogrammingmechanismsviaenergetic
control of function and oxidation. Through regulation of
many biological functions including mitochondrial activity,
cellular stress, inﬂammation, and telomere shortening, the
dietary signature starts when epigenetic mechanisms induce
or limit the risk to disease [28]. Possible levels of expression
of a certain gene lie in a range of disease susceptibility that
is determined by epigenetic mechanisms. These mechanisms
are dictated by the functional proﬁle of the cell, which obeys
its nutritional state and reﬂects the nutritional environment.
(3) Although sustainability of epigenetic programming
along life span is not well understood [28], two tem-
porally distinct proﬁles may be distinguished. First, the
basal epigenome is determined early on in life. Depend-
ing on the basal expressivity of DNA, it behaves like a
permanently edited version of the genome. Accordingly,
increasing evidence of trans-generational inheritance of
epigenetics was found in mice [29] through the eﬀect of
grandmaternal nutrition on grandchildren during gamete
stage, throughout the mother’s fetal stage [30]. Second,J o u r n a lo fN u t r i t i o na n dM e t a b o l i s m 3
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Figure 1: Map of the Middle East and North Africa (MENA) region. The MENA region includes countries such as Algeria, Armenia, and
Turkey, that are not members of the WHO Eastern Mediterranean Region (EMR) that is referred to in the literature.
later in life, similar mechanisms aﬀect gene expressivity in
response to temporary environmental factors, resulting in a
short-lived epigenetic proﬁle. These changes are mainly due
to interference of nutrients and bioactive food components
with transcription factor conformations [26]. This signature
serves as a means for the organism to receive information
about its nutritional environment in order for the cells to
executeappropriatemodiﬁcationsontheproﬁleofexpressed
genes [31]. The nutrigenomic signature is not well studied
in humans yet; however obvious importance is due to its
impact on gene expression, chronic diseases susceptibility,
and health status of future generations [31–33].
(4) Regulators of posttranscriptional modiﬁcations aﬀect
alternative RNA splicing which gives rise to diﬀerent mature
mRNA isoforms. Alternative splicing is as highly prevalent
as in 35 to 59% of human genes [34]. Post-trancriptional
regulators, such as microRNAs and their coacting and
counteracting proteins, are part of the RNA and protein
pools [35]. They are hence inﬂuenced by epigenetic and
metabolic factors as well [26, 36].
(5) Proteomics is the study of the protein pool in the
organism, as an integral part of the cellular function. On
the other hand, the metabolome designates the structure,
the localization, the post-translational modiﬁcations, and
the functions of proteins and metabolites along with their
interactions in the organism [37]. It deﬁnes the current
metabolic state and active intracellular pathways in the
organism (Figure 5). The functional gene products com-
prise all the potentially functional molecules and pathways,
whether currently active or not, that result from a certain
genome-epigenome combination, leading to a certain range
of possible phenotypic outcomes, rather than a clearly
deﬁned health status.
(6) Nutrigenetics is a quite diﬀerent approach that
emerged when dietary interventions were able to successfully
alter the course of certain diseases. The basic principle con-
siders how the same dietary environment can result in diﬀer-
entphenotypicoutcomesofhealthordiseaseinmetabolizers
with diﬀerent functional gene-products or programmed
phenotypes [38]. The concept is similar to how individuals
possessdiﬀerentphenotypesasdrug-metabolizers.Thestudy
of genetic variations aﬀecting nutrient metabolism, from
digestion to detoxiﬁcation, can decipher ambiguities in the
diet-disease relationship [38]. However, the challenge lies in
the ability of researchers to describe the processes through
which the dietary environment imposes itself to precipitate
metabolic disorders.
(7) Finally, hypotheses of Thrifty Proﬁle, namely thrifty
genes and thrifty phenotypes, oﬀer explanations for etiology,
predisposition, and rising prevalence of DM and obesity.
Early life dietary habits foretell the basal appetite control
and cellular nutritional needs through psychological and
molecular habituations [28]. Thrifty genes that enable
survival during periods of food shortages may have been
conserved over generations under the selection pressure of
under-nutrition [39]. Thrifty phenotypes may be due to
early nutritional challenges that enhance nutrients-saving
mechanisms in the growing individual, leading to excessive4 J o u r n a lo fN u t r i t i o na n dM e t a b o l i s m
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Figure 2: Increasing prevalence of diabetes mellitus in the MENA. (a) General increase in reported prevalence (%) of Type 2 Diabetes
Mellitus in the MENA between the years 2000 and 2010. Numbers are reported as approximated by the International Diabetes Federation
[12–15]. The expected 2-fold increase for the year 2030 is approximated based on demographic parameters, without accounting for changes
in age strata or other risk factors [16]. (b) Overall growth in annual incidence (per 100,000) of Type 1 diabetes mellitus in children younger
than 14 years old in the MENA. Numbers are estimations by the International Diabetes Federation based on various years between 1986 and
2000 [12–15].
storage later on and increased risk of metabolic disorders
[40].Bothmodelshavenotgatheredenoughevidenceapiece;
however combined they provide a fertile base for further
nutritional genomic research.
An example of a phenotype that has evolved accord-
ingly is taste preferences and ability to digest, absorb, and
appropriately respond to nutrients [41]. Genes for taste
receptors, among other proteins that handle the metabolism
of diﬀerent nutrients, have been extensively studied. In an
extensivereviewbyGarcia-Bailoetal.,animportantaspectof
the dietary signature is addressed: the genetic variations that
aﬀect dietary habits and food choices, with an emphasis on
their eﬀects on the nutritional environment and the health
outcome [41].
Given the rise in multifactorial diseases, nutrigenet-
ics started to involve public health research, hinting at
personalized dietary recommendations for prevention of
civilizationdiseasesmanyyearsbeforeclinicalmanifestations
arise[31].Adequacyofthegeneraldietaryrecommendations
to the ancient nature of our genes is becoming increas-
ingly dubious. The human genome, as we know it, was
sculpted throughout 2 million years of evolution under
the diets of our hunters-gatherers ancestors [42]. Later on,
the available food choices changed since the introduction
of agriculture, but too rapidly for the ancestral stone-age
genome to keep up with. This fast nutritional transition
revealed evolutionary origins of obesity and diabetes among
other civilization epidemics [43]. The experiment-based
advancementofdietaryrecommendationsduringthepast25
years showed a convergence towards what looks more like a
Paleolithichunter-gathererdiet[44].Despitelowcompliance
to recommended diets and increasing industrialization ofJ o u r n a lo fN u t r i t i o na n dM e t a b o l i s m 5
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Figure 3:IncreasingprevalenceofobesityintheMENA.Prevalence
(%) of obesity increased in both men and women in countries of
the MENA between 2004 and 2008. Numbers are WHO estimates
in World Health Statistics of 2005 and 2011. Totals of men and
women are integrated for purposes of comparative illustration and
do not represent adjusted arithmetic total prevalences. Obesity
was deﬁned as body mass index (BMI) ≥30Kg/m2.O b e s i t yd a t a
about Jordanian men in 2004 are not available, but prevalence was
estimated to be less than that of women [17, 18]. KSA: Kingdom of
Saudi Arabia; UAE: United Arab Emirates.
actual dietary habits, personalized and ancestral dietary
recommendations still seem promising.
4. NutritionalGenomics in the MENA
Diet, genetics, and disease are linked in many ways as
could be shown in Figure 5. The MENA is a region that
has been witnessing simultaneously a dietary change and a
worsening prevalence of chronic diseases. Because of this,
nutritional genomics research in such a region can improve
our understanding of this rapid change in disease prevalence
and shed light on the genomic eﬀects of this dietary
transition in the region. Nutritional genomics research in
the MENA is minimal. To our knowledge, this is the ﬁrst
review on the topic in the region. We aim to collate studies
in MENA countries that discuss any aspect of the dietary
signature that we discussed in Figure 5. We approach that
using examples of common diseases with rising prevalence
in the MENA. The paper discusses two categories of diseases:
(1) civilization disorders of metabolism (cardiovascular
diseases and metabolic risk factors), and (2) micronutrient
deﬁciencies (MNDs).
We also look at other populations where nutritional
genomics research in these disease categories was done and
discuss how it applies to our region with recommendations
for future research on MENA populations.
5.Diet-RelatedCivilizationDisordersof
Metabolism inthe MENA Region
Populations of the MENA belong to a unique genetic
pool because of the mixture of ethnicities with horizontal
mixing of populations throughout history, the high rate of
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Figure 4: Expected overall increase in mortality due to cardiovas-
cular diseases in the MENA [19]. CAD: Coronary Artery Disease;
CVE: Cerebrovascular Event.
consanguineous marriages within subpopulations, and the
geography of the states making up the region (Figure 1).
Nevertheless, wide prospective population studies on the
eﬀectsofpolymorphismsonsuchdisordersofmetabolismin
the MENA are still lacking [25]. Based on literature reports
on other populations, a large set of genes and DNA sequence
variants are potentially culpable of the rise of metabolic
disorders under the eﬀect of industrialized diets. In this
part of the paper, we present numerous polymorphisms
that predispose to metabolic disorders including T2DM,
obesity, dyslipidemias, atherosclerosis, cardiovascularevents,
and hypertension. The civilization disorders have common
pathophysiologies and risk factors of metabolism and, since
interrelated and comorbid, will accordingly be treated as
one major health outcome in the following discussion about
genetic entities common to the diﬀerent disorders, under the
eﬀect of diet.
TheBrain-DerivedNeurotrophicFactor (BDNF)isimpor -
tant for energy balance in mice and for regulation of
stress response in humans (OMIM 113505). Polymorphisms
in this gene are associated with obesity and all subtypes
of psychological eating disorders in Europeans (NCBI
627). Recently, three-way association was identiﬁed between
hoarding behavior of obsessive-compulsive disorder, obesity,
and the Val/Val genotype of BDNF in the Valine (Val)
to Methionine (Met) amino acid change at position 66
(Val66Met) in Caucasians [45]. The suggested evolutionary
mechanism for this complex relationship between gene,6 J o u r n a lo fN u t r i t i o na n dM e t a b o l i s m
Table 1: Rates of cardiovascular disease, hypertension, and the metabolic syndrome in MENA countries from diﬀerent studies.
Coronary artery disease (CAD)
Iran Age-adjusted prevalence (%) 12.7 Nabipour et al. [73]
Jordan Prevalence (%) 5.9 Nsour et al. [74]
Saudi Arabia,
(rural) Prevalence (%) 4.0 Al-Nozha et al. [75]
(urban) Prevalence (%) 6.2
(overall) Prevalence (%) 5.5
Tunisia Prevalence (%), [men] 12.5 Ben Romdhane et al. [76]
Prevalence (%), [women] 20.6
Cerebrovascular Accidents
Bahrain Age-adjusted incidence (per 100,000) 96.2 Al-Jishi and Mohan [77]
Iran Age-adjusted incidence (per 100,000) 61.5 Ahangar et al. [78]
Kuwait Age-adjusted incidence (per 100,000) 92.2 Abdul-Ghaﬀar et al. [79]
Libya Age-adjusted incidence (per 100,000) 114.2 Radhakrishnan et al. [80]
Palestine Age-adjusted incidence (per 100,000) 62.7 Sweileh et al. [81]
Qatar Age-adjusted incidence (per 100,000) 123.7 Hamad et al. [82]
Saudi Arabia Age-adjusted incidence (per 100,000) 38.5 Al-Rajeh et al. [83]
Hypertension (HTN)
Algeria Prevalence (%), [Age > 25] 36.2 Yahia-Berrouiguet et al. [84]
Bahrain Prevalence (%), [Age > 20] 42.1 Al-Zurba [85]
Egypt Age-adjusted prevalence (%) 27.4 Ibrahim et al. [86]
Prevalence (%), [Age > 25] 26.3 Galal [87]
Iran Prevalence (%), [Age > 19] 25.6 Sarraf-Zadegan et al. [88]
Prevalence (%), [Age: 30–55] 23.0 Haghdoost et al. [89]
Prevalence (%), [Age > 55] 49.5
Iraq Prevalence (%), [Age > 20] 19.3 WHO: STEPwise, [90]
Jordan Prevalence (%), [Age > 18] 30.2 Zindah et al. [91]
Lebanon Prevalence (%), [Age: 18–65] 31.2 Sibai et al. [92]
Morocco Prevalence (%), [Age > 20] 33.6 Tazi et al. [93]
Oman Prevalence (%), [Age > 20] 21.5 Hasab et al. [94]
Palestine (WB),
(rural) Prevalence (%), [Age: 30–65] 25.4 Abdul-Rahim et al. [95]
(urban) Prevalence (%), [Age: 30–65] 21.5
Qatar Prevalence (%), [Age: 25–65] 32.1 Bener et al. [96]
Saudi Arabia Prevalence (%), [Age: 30–70] 26.1 Al-Nozha et al. [97]
Sudan Prevalence (%), [Age: 25–64] 23.6 WHO: STEPwise, [90]
Syria Prevalence (%), [Age: 18–65] 40.6 Maziak et al. [98]
Turkey Age-adjusted prevalence (%) 25.7 Sonmez et al. [99]
UAE Prevalence (%), [Age > 20] 20.8 Baynouna et al. [100]
Yemen Prevalence (%), [Age > 35] 26.0 Gunaid and Assabri [101]
Middle East Prevalence (%), (overall) 21.7 Motlagh et al. [102]
Metabolic Syndrome
Algeria Prevalence (%), [Age > 20] 17.4 Mehio Sibai et al. [103]
Iran Prevalence (%), [Age > 19] 23.3 Mehio Sibai et al. [103]
Jordan Prevalence (%), [Age > 18] 36.3 Khader et al. [104]J o u r n a lo fN u t r i t i o na n dM e t a b o l i s m 7
Table 1: Continued.
Kuwait Prevalence (%), [Age > 20] 24.8 Al Rashdan and Al Nesef [105]
Lebanon Prevalence (%), [Age: 18–65] 25.4 Mehio Sibai et al. [103]
Morocco, (rural) Prevalence (%), [women] 16.3 Rguibi and Belahsen [106]
Oman,
(overall) Prevalence (%), [Age > 20] 21.0 Al-Lawati et al. [107]
(Nizwa) Age adjusted prevalence (%) 8.0 Al-Lawati et al. [107]
Palestine (WB) Prevalence (%), [Age: 30–65] 17.0 Abdul-Rahim et al. [95]
Qatar Prevalence (%), [Age > 20] 27.7 Musallam et al. [108]
Age adjusted prevalence (%) 26.5 Bener et al. [109]
Saudi Arabia Age adjusted prevalence (%) 39.3 Al-Nozha et al. [110]
Tunisia Prevalence (%), [Age > 20] 16.3 Bouguerra et al. [111]
UAE Prevalence (%) 39.6 Malik and Razig [112]
Nonadjustedratesfromdiﬀerentstudiesarenotvalidforcomparisonbutdisplayedtopresenttheburdenofthemorbidities.HTNisdeﬁnedasBP >140/90or
useofantihypertensivemedications.MetabolicSyndromedeﬁnitionisbasedonAdultTreatmentPanelIII,exceptforPalestineandTunisiawhere,respectively,
WHO criteria and hypercholesterolemia (Total Cholesterol ≥5.2mmol/l) instead of low HDL cholesterol were used. UAE: United Arab Emirates; WB: West
Bank [103, 113–116].
psychopathology, and body weight is the conservation of a
thrifty gene, once an old survival strategy.
Control of fetal appetite was recently shown to be a
function of the Fat Mass- and Obesity-Associated (FTO)g e n e
expression [28] which codes a nuclear oxygenase that aﬀects
tissue lipid metabolism [46] (NCBI 79068) and depends on
energy balance during development [28]. A strong relation
links FTO SNPs to higher risk of obesity and T2DM in many
international studies (OMIM 610966) [47, 48].
Transcription Factor 7-Like 2 (TCF7L2)g e n ec o d e sa
transcription factor involved in blood glucose homeostasis.
The rs7903146 variant association to T2DM varies greatly
over ethnicities (OMIM 602228). However in Palestinians,
thisSNP(114758349C >T)increasestheriskforT2DM,and
homozygotes are aﬀected at younger age [49].
Calpain 10 (CAPN10), which codes a calcium-dependent
cysteine protease, is being increasingly studied for its role
in T2DM (NCBI 11132). SNP-44 of CAPN10 has signiﬁcant
association with T2DM and total cholesterol in Gaza [50],
while only UCSNP-19 SNP and haplotype-111 are proven to
be high risks for T2DM in Tunisia [51].
The association of T2DM with polymorphisms of the
Angiotensin Converting Enzyme (ACE) and the Methylene
Tetrahydrofolate Reductase (MTHFR)i sn o tw e l lp r o v e n[ 52].
However data in Tunisians suggest synergistic action of the
ACE Insertion/Deletion (I/D) dimorphism with the MTHFR
C677T SNP on risk of T2DM [52]. Fairly common, ACE D
and MTHFR 677T alleles are, respectively, present in around
77 and 27% of Moroccans [53]. Nevertheless, ACE DD
genotype in Tunisians is associated with higher ACE activity
and might become a useful clinical marker for CAD risk
assessment of acute myocardial infarction [52, 54]. In
Lebanon, ACE D allele and age, combined, are associated
with higher risk for hypertension [54]. Also, Lebanese with
MTHFRC677Tturnedouttobemoresusceptibletodiabetic
nephropathy than Bahrainis with the same SNP [55]. The
SNP cannot constitute an independent risk factor in Arabs
[56]. Its eﬀect is presumably due to high homocysteine levels
and hence must be evaluated depending on dietary and
ethnic backgrounds [55].
In genes encoding the G protein-coupled Beta-2- and
3-Adrenergic Receptors (ADRB2, ADRB3),e v o l u t i o n a r y
selection of speciﬁc alleles exists in Africans, Asians, and
Europeans. ADRB2 Glu27 and Gln27 are, respectively, fac-
tors of exercise-dependent obesity risk and metabolic syn-
drome susceptibility (OMIM 109690). Glu/Glu and Glu/Gln
can independently predict severe Coronary Artery Disease
(CAD) in Saudi Arabs [57]. However ADRB3 Trp64Arg SNP
is a CAD predictor only in presence of other risk factors
in Arabs, but not an independent one [57]. ADRB3 is
mainly located in adipose tissues causing easier weight gain
and earlier T2DM onset in Trp64Arg individuals in several
populations [58] (NCBI 155) (OMIM 109691).
Peroxisome Proliferator-Activated Receptor Gamma
(PPARG) genes encode nuclear receptors and regulators of
adipocyte diﬀerentiation and possibly lipid metabolism and
insulin sensitivity (OMIM 601487). Pro12Ala isoform of
PPARG2 seems to activate transcription less eﬀectively and
carry less morbidity. Carriers of a Pro12Ala polymorphism
may have a weaker BMI correlation to amount of dietary fat
when compared to Pro homozygotes [59], while response to
quality of dietary fat is greater in terms of BMI, lipid proﬁle,
andfastinginsulinlevels[60,61].Howevertheseassociations
were not found for many of the studied populations (OMIM
601487).
Apolipoproteins (APOs) are involved in lipid metab-
olism. APOE polymorphisms have been heavily studied. In
the APOE G219T SNP, TT individuals have prolonged post-
prandial lipemia [62]. Apo E has three major isoforms, E2,
E3, or E4. APOE E4 individuals may be protected eﬀectively
by lower dietary fat intake [63] while non-E4 individuals
haveminimaltonobeneﬁtfromdietaryinterventiononlipid
proﬁle [64]. In Iranians, E2 allele was associated with lower
total cholesterol levels [65]. However, despite correlation8 J o u r n a lo fN u t r i t i o na n dM e t a b o l i s m
Table 2: Rates of Vitamin D deﬁciency and iron deﬁciency in MENA countries from diﬀerent studies.
Vitamin D deﬁciency (VDD)
Iran Prevalence (%), [girls], [adolescent] Up to 70 Moussavi et al. [143]
Jordan Prevalence (%),
[adult females] 37.3 Batieha et al. [144]
[adult males] 5.1
Lebanon Prevalence (%),
[girls] 32 El-Hajj Fuleihanet al.
[145, 146]
[boys] 9–12
Morocco (Rabat) Prevalence (%), [women] 91 Arabi et al. [147]
Saudi Arabia Prevalence (%), [girls], [adolescent] Up to 80 Siddiqui and Kamfar [148]
Tunisia (Ariana) Prevalence (%), [women], [Age: 20–60] 47.6 Arabi et al. [147]
Turkey (Ankara) Prevalence (%),
[mothers] 46 Arabi et al. [147]
[newborns] 80
Iron deﬁciency
Arab Gulf countries Prevalence (%),
[children], [preschool age] 20–67 Musaiger [149]
[children], [school age] 12.6–50
[pregnant women] 22.7–54
Bahrain Prevalence (%),
[children], [Age: 6–59 months] 48 Bagchi [150]
[women], [Age: 15–49] 37.3
Egypt Prevalence (%),
[children], [Age: 6–59 months] 25 Bagchi [150]
[women], [Age: 15–49] 11
Iran Prevalence (%),
[children], [Age: 6–59 months] 15–30 Bagchi [150]
[women], [Age: 15–49] 33.4
Jordan Prevalence (%),[children], [school age] 20 Bagchi [150]
Prevalence (%), [women], [Age: 15–49] 28
Lebanon Prevalence (%), [children], [Age: 6–59 months] 23 Bagchi [150]
Morocco Prevalence (%),
[children], [Age: 6–59 months] 35 Bagchi [150]
[women], [Age: 15–49] 30.1
Oman Prevalence (%),
[children], [Age: 5–14] 41 Bagchi [150]
[women], [Age: 15–49] 40
Pakistan Prevalence (%),
[children], [Age: 6–59 months] 60 Bagchi [150]
[women], [Age: 15–49] 30
Palestine Prevalence (%),
[children], [Age: 6–59 months] 53 Bagchi [150]
[women], [Age: 15–49] 36.2
Saudi Arabia Prevalence (%), [children], [preschool age] 17 Bagchi [150]
Syria Prevalence (%),
[children], [Age: 6–59 months] 23 Bagchi [150]
[women], [Age: 15–49] 40.8J o u r n a lo fN u t r i t i o na n dM e t a b o l i s m 9
Table 2: Continued.
UAE Prevalence (%),
[children], [Age: 6–59 months] 34 Bagchi [150]
[pregnant women] 14
Yemen Prevalence (%), [children], [preschool age] 70 Bagchi [150]
Diﬀerent limits of blood levels deﬁne VDD, ranging from insuﬃciency to severe deﬁciency, similar for Iron deﬁciency. UAE: United Arab Emirates [147, 150].
between APOE2 and LDL subfraction proﬁles in healthy
Arabs, no similar association was found in Arabs with CAD
[66]. APOE E2, E3, and E4 carriers constitute approximately
11, 79, and 10% of Moroccans, respectively [53].
Moreover, mutations in Lipoprotein Lipase (LPL), which
is crucial for receptor-mediated lipoprotein uptake, drasti-
cally aﬀect lipoprotein metabolism disorders (NCBI 4023).
In Saudi Arab population however, lack of association
between LPL polymorphisms and CAD was noticed [56].
Strong evidence exists for Hepatic Lipase (LIPC) C514T
homozygotes. They have more atherogenic lipid proﬁle in
response to dietary fat in addition to impaired adaptation
to higher animal fat with higher cardiovascular diseases risk
[67, 68].
Finally, the Paraoxonase (PON1)g e n ee n c o d e sf o ra n
anti-atherosclerotic esterase which capacitates high-density
lipoproteins to prevent lipoprotein oxidation. Gln192Arg
and Leu55Met are two common polymorphisms of PON1
that modulate PON1 activity in the serum, which predicts
the architecture of apolipoprotein, lipoprotein, and lipid
levels [69]. In the late 1990s, PON1 status, including
genotype and serum activity levels, has been proven to
predict cardiovascular risk much better than genotype alone
[70]. However, in Turkish subjects, there was no consistent
association between the polymorphisms and the lipid levels
[71]. An individual’s polymorphism might be suggestive of
a high risk while his dietary signature is making the actual
PON1 activity favorable, that is, low risk. This interaction
between diet and genes can hinder the signiﬁcance of genetic
screening, and enhance the relevance of proteomics and
metabolomics. The lesson learned from the PON1 role in
cardiovascular disease is of utmost relevance. Functional
genomic analysis is required for adequate risk assessment;
an individual may be screened for all known polymorphisms
of PON1, but still not be assigned a risk category for
cardiovascular disease [72].
Discrepancies between genotype and function impose
limitations on genetic screening. Similarly for most of the
polymorphisms presented previously, the degree to which
genetic screening can be helpful in decision-making is
controversial. More activity correlation studies are needed
to examine the “penetrance” of polymorphisms. Also, insuf-
ﬁcient nutrigenomic and proteomic evidence may be mis-
leading [117]. Hence, further multidisciplinary studies, with
coordination between laboratories, will be needed to decide
which gene/polymorphism would be worth screening in a
particular population.
Further multidisciplinary nutritional genomics research
is needed for more speciﬁc targeted individualized advising
and therapy. However, given the current lack of adequate
understanding of the genetic etiologies of civilization dis-
eases and wide-scale regional genetic screening studies,
reversal of dietary changes is rendered the simplest available
measure to control the metabolic epidemic of civilization
diseases in the MENA.
6. MicronutrientDeﬁciencies (MNDs) in the
MENA Region
Micronutrients (vitamins and minerals) are required
throughout life, in minute amounts in the human body, to
functionascofactorsofenzymesorasstructuralcomponents
of proteins, or to maintain genome stability, among other
physiological roles [118]. Both their excess and deﬁciency
may cause DNA damage, alter growth and development,
contribute to a wide array of chronic diseases, and jeopardize
health [118]. MNDs are highly prevalent in MENA countries
as was established earlier. Deﬁciencies in iodine, iron, and
vitamin A are very important MNDs in terms of prevalence
and potential threat to public health worldwide; however
relevant gene-diet interaction has not been suﬃciently
studied in the MENA. This section will thus be restricted to
the following MNDs of particular interest in diet-genetics-
disease interaction: vitamin D, calcium, iron, folate, and
vitamins C, E, B6, and B12.
6.1. Vitamin D Deﬁciency (VDD). Vitamin D is a fat-soluble
vitamin, with two forms, one present in a narrow range of
foods(D2)andanotherformedundertheskinwhenexposed
to the ultraviolet B (UVB) light fraction of sunlight (D3);
both are activated by the liver and kidneys [119]( Figure 6).
Prolonged VDD can result in rickets in young children and
osteoporosis and fractures in adults [120]. Recently, low
vitamin D levels have been associated with increased risk
of hypertension, cardiovascular diseases [121], cancer [122],
diabetes[123],musculoskeletalandimmunitydisorders,and
infectious diseases [124].
Despite the sunny climate, the MENA has a highly
prevalent VDD across all age groups, with the highest rate
of rickets worldwide [22]. The main reasons are limited
sun exposure and low dietary vitamin D intake, along
withfrequentpregnancies,shortbreastfeedingperiods[125],
skin pigmentation [126], body mass index [127], religious
practices [128], and educational levels [129].10 J o u r n a lo fN u t r i t i o na n dM e t a b o l i s m
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status surrounding the primarily translated proteome, the ﬁnal set of functional proteins, activated pathways, and subsequent metabolites
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downstream end result of health status depends greatly on what nutrients are fed into the systemic machine of gene products. The functional
gene product is the end-point in nutrigenomics and the starting point in nutrigenetics. It is a marker of the phenotypic outcome: expression
of disease and prognosis. Phenotype may dictate the lifestyle choices available to a certain individual, including taste preferences, which are
also delineated by culturally inherited customs and habits. In their turn, lifestyle choices including dietary habits determine environmental
exposures. Furthermore, civilization diseases have been hidden for a long period of time due to the sociocultural inheritance of adequately
evolved matching lifestyle preferences and diet choices that have been masking a biologically inherited limited gene pool. The genes being in
statusquo,inpresenceofanutritionaltransition,theratesofcivilizationdiseasesareontherisebecauseofthelossoftheprotectiveadequacy
of the diet. This highlights the presence of hidden genes, the phenotypic expression of which can be masked by a speciﬁc nutritional state,
such as that corresponding to the Mediterranean diet, as more increasingly being recommended recently in the literature. However this
cannot be answered if sequence variations and speciﬁc SNPs aﬀecting nutritional needs are not tested for in the speciﬁc populations.
In addition to nutritional and social factors of VDD,
genetic factors also play an important role and are depicted
on the metabolic pathway of vitamin D shown in Figure 6.
Genetic variations predisposing to VDD are related to
Vitamin D Receptor (VDR) polymorphisms at intron 8
( B s m I )a n de x o n2( F o k I )[ 130]. The Fok1 polymorphism
(C>T) in the translation initiation site creates an upstream
initiation codon and a three amino acids longer molecule
in the f allele compared to the F allele [131] which gives
a more transcriptionally active VDR [132] leading to the
tolerance to low vitamin D levels observed in Egyptian
FF homozygotes [130]. This suggests possible evolutionary
adaption to dietary intake or lifestyle changes. Only FF
homozygote children have increased calcium absorption
and bone mineral density [131]. Conversely, the decreased
calcium absorption linked to the f allele was correlated
with an increase in colon cancer risk only when calcium
dietary intake is low [133]. FF genotype seems hence more
advantageous than ﬀ genotype. Paradoxically, FF (shorter
VDR) was correlated with rickets unlike ﬀ (longer VDR) in
Turks and Egyptians. Thus, further studies are needed to
understand the complex genetics and risks of rickets. VDR B
allelealsopredisposestoVDDsinceEgyptianBhomozygotes
had severe rickets [130]. In other studies in the Middle East,
high vitamin D doses were needed to treat patients with
rickets [134]. Thus, the unexpected high prevalence of VDD
in the MENA could be linked to VDR polymorphisms.
Moreover, a G>A polymorphism at position −3731 of
the cdx-2 (Caudal-Type Homeobox Transcription Factor)
binding element on the VDR gene promoter is another
genetic variant of VDR that aﬀects calcium absorption. The
Cdx2 promoter A allele (cdx-A) binds cdx2 more strongly
and has a greater transcriptional activity compared to the
cdx-G allele. Thus, the A allele may increase intestinal
VDR expression, subsequently enhancing calcium intestinal
absorption and increasing bone mineral density. The dif-
ferential expression of VDR shows how genetic diﬀerences
inﬂuence the body response to nutrients [135].
Bioactive food components may exert an eﬀect on gene
expression and enzyme activity, subsequently decreasing dis-
ease risk. For example, 4 ,5,7-Trihydroxyisoﬂavone (genis-
tein), a soy component, is a genome-protective nutrient.
It inhibits the activity of CYP24A1 (Figure 6)a n dt h u s
1,25(OH)2D degradation, increasing VDR stability and the
half-life and biological eﬀects of vitamin D [136]. Folate
can also inhibit this activity by increasing methylation ofJ o u r n a lo fN u t r i t i o na n dM e t a b o l i s m 11
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the promoter of CYP24A1. Also, addition of vitamin D
and calcium to the western diet signiﬁcantly decreases the
incidence of colon cancer [133].
6.2. Iron Deﬁciency. Iron (Fe) is an essential mineral needed
in small amounts mainly for the production of hemoglobin
and utilization of oxygen among other vital functions.
I r o nd e ﬁ c i e n c yi sac o m m o nM N Dm o s t l yc a u s e db yl o w
intake of iron, blood loss, and parasitic infections [137].
Iron absorption is enhanced by vitamin C, low pH, and
heme iron and hindered by bioactive vegetables components
(polyphones, tannins, phytates) and calcium [138].
Genetic factors that contribute to iron deﬁciency, in
addition to the dietary intake, are underscored by the
ability of many individuals to maintain normal iron levels
despite low iron dietary intake. Nutritional iron deﬁciency
and genetic iron deﬁciency have been experimentally dis-
tinguished in mice. Hephaestin (Heph) is a multicopper
oxidase that allows iron basolateral surface export. Sex-
linked anemia (Sla) mice bearing a deletion in Heph gene
compared to control mice showed diﬀerent responses to diet;
Sla mice had duodenal iron accumulation and low plasma
iron [139]. Additionally, mutations in the genes of human
hemochromatosis protein (HFE) and its interacting protein
beta-2 microglobulin (B2M), which play an important role
in iron metabolism, cause murine iron deﬁciency [140].
6.3. Folate Deﬁciency. Folic acid is a water soluble B vitamin
of exclusive dietary origin. It provides the one-carbon
metabolism with its main coenzyme form, tetrahydrofolate
(THF). A key enzyme herein, methylenetetrahydrofolate
reductase (MTHFR), catalyzes vitamin B12-dependent con-
version of homocysteine to methionine, a precursor of S-
adenosylmethionine (SAM), a methyl donor to DNA [141].
Thus, folate deﬁciency results in hyperhomocysteinemia
(HHC), a risk factor for CAD [142].12 J o u r n a lo fN u t r i t i o na n dM e t a b o l i s m
MTHFR C677T is prevalent in 4% of Pakistanis [32], 2%
of Yemenite Jews, 10% of Muslim Arab Israelis, and 11% of
Lebanese [151]. It leads to a thermolabile MTHFR, which
precipitatesHHCinlowfolatestates.Thisgene-environment
combinationisarisk factorforcardiovasculardiseases[152],
neural tube defects, and other chronic diseases [153].
C677T is a genetic variation that aﬀects individual
dietary requirements because it makes prevention of folate-
related diseases that require higher folate intake. Korean C
homozygotes develop HHC only with low folate levels, while
T homozygotes have HHC even with normal folate levels
[154].Surprisinglyhowever,thehyperhomocysteinemia,low
folate levels, and increased cardiovascular risk observed
in Indian Asians compared to European whites were not
attributedtotheMTHFR677Tvariant[155].Studiesspeciﬁc
to the MENA are therefore needed because of possible
variations from other regions.
The example of MTHFR and folate also underscores the
genome-epigenome interplay. The TT genotype alters DNA
methylation and gene expression in peripheral blood
mononuclear cells only in folate deﬁcient patients [156].
Paradoxically,thesamepolymorphism isinverselyassociated
with and hence has a protective role against colorectal
cancer (CRC). CRC risk decreases with adequate methionine
intake, which leads to an increased formation of SAM and a
negative feedback inhibition of MTHFR activity. However,
the protective roles of MTHFR mutation and methionine
dietaryintakerequireanadequatedietaryfolateintake[157].
These ﬁndings suggest that inadequate folate intake puts
carriers of particular genetic variants at higher risk of cancer.
Thus personalized dietary interventions might be beneﬁcial
in reducing cancer risks.
Serum vitamin B12 deﬁciency is highly prevalent in
Iran [158]. Thus, low folate and vitamin B12 levels can
be inversely linked to the hyperhomocysteinemia observed
in this population. Importantly, high prevalence of CAD
was observed in a Turkish population with low plasma
folate despite low plasma cholesterol concentrations [159]. It
remains to determine the link between hyperhomocysteine-
mia, low folate intake, CAD risk, and MTHFR variants, to
explain this prevalence in Turkey and possibly in other coun-
tries of the MENA region. This would add folate supplemen-
tation as a possible treatment for hyperhomocysteinemia.
Other studies have also reported the possible contribution
of the level of pyridoxal phosphate (PLP or vitamin B6)
to hyperhomocysteinemia and vascular disease; low PLP
levels were observed in individuals with the homozygote
TT genotype compared to healthy individuals from some
countries of the MENA [160, 161]. These data corroborate
the various dietary signatures on the speciﬁc genetic proﬁle
and show that other mechanisms, enzymes, and vitamins
should be examined as well.
6.4. Vitamin B12 Deﬁciency. Like folate deﬁciency, vitamin
B12 (cobalamin) deﬁciency can aﬀect establishment of the
disease depending on the genetic background. A common
genetic variant is detected in Methionine Synthase Reductase
(MTRR), an important enzyme for maintaining Methionine
Synthase in its active state. The polymorphism is an A66G
substitution resulting in an Ile22Met residue. The homozy-
gousgenotypewasassociatedwithanincreasedriskofneural
tube defects (NTDs) when combined with low vitamin
B12 levels. Vitamin B12 deﬁciency is highly prevalent
among Iranian women of childbearing age [158]. However
polymorphisms in both MTHFR and MTRR increase NTDs
risk [162].
6.5. Vitamins C and E Deﬁciencies. As antioxidants, vita-
mins C and E have an important function in the diet-
gene interaction. Glutathione S-transferases (GSTs) transfer
glutathione to diﬀerent substrates. A common deletion of
GSTM1 gene, a deletion polymorphism in GSTT1,a n da n
A313G polymorphism of GSTP1 result, respectively, in a
nonfunctional genotype, loss of enzyme activity, and altered
activity of the GST isoforms. The GST enzymes were found
protective against serum ascorbic acid deﬁciency when vita-
min C consumption is low, since GST null genotypes with
low vitamin C intake had an increased serum ascorbic acid
deﬁciency risk [163]. The Hp1 and Hp2 polymorphisms in
the hemoglobin-binding protein haptoglobin (Hp) were also
studied in vitamin C deﬁciency. Unlike Hp1 carriers, Hp2
homozygotes had lowest serum vitamin C concentrations
when dietary vitamin C intake is insuﬃcient. Thus, Hp1 has
a greater antioxidant capacity preventing hemoglobin-iron-
related vitamin C oxidation and depletion [164].
A protective role for vitamin E against atherosclero-
sis, cancer, and neurodegenerative diseases has also been
reported. Polymorphisms in the proteins involved in vitamin
Em e t a b o l i s ml e a dt od i ﬀerential vitamin E uptake and
response among individuals, and subsequently diﬀerent
disease risk [165]. Dietary vitamin E intake also inﬂu-
ences the body mass index (BMI) and risk of obesity via
modifying genetic variants of SIRT1 (sirtuin protein family
of nicotinamide-adenine-dinucleotide- (NAD+)-dependent
histone deacetylases) [166].
Well-studied gene-diet interactions are also critical in
the pathophysiology of cancer. Given the evidence that VDR
polymorphisms, MTHFR genotype, and DNA methylation
in a low calcium or folate intake are associated with an
increased cancer risk, the dietary signature greatly inﬂuences
carcinogenesis. Signiﬁcant dietary factors include antioxi-
dants such as vitamin C, carotenoids, lycopene, tocopherols
(vitamin E), and many other micronutrients present in fruits
and vegetables.
Being one of the leading causes of death worldwide as
well as in the MENA, cancer has been extensively studied,
and the diet-genetics-cancer interaction is currently being
thoroughly investigated for each and every one of the
involved micronutrients. So, the eﬀect of the diet-genetics
interactiononcarcinogenesiswillnotbedwelleduponinthis
paper.
The aforementioned studies collectively depict the inter-
action between diet, genetic variability, and disease. Genetic
variants might aﬀect gene expression patterns and epigenetic
events resulting in diﬀerential body responses to diet. How-
ever, a small individualized nutritional intervention that is
well studied to provide the needed concentrations of micro-
nutrients can inﬂuence genetic variants to decrease diseaseJ o u r n a lo fN u t r i t i o na n dM e t a b o l i s m 13
risk. Thus, nutrigenetics is a tool for choosing the appropri-
ate diet according to the individual’s genetic makeup.
7. A Call for Nutritional Genomics
Research inthe MENA
All previous data support the crosstalk between diet and
genome. Diﬀerential responses to dietary components
among individuals are determined by genetic factors. The
deleterious eﬀects of some genotypes can be circumvented
by an increased intake of particular nutrients to overcome
the genetic susceptibility, which opens the horizon for
personalized diet. In turn, nutrients might aﬀect genome,
gene expression, and phenotype. Although hard and com-
plex, it is worthwhile to identify the genes that predispose
individualstochronicdiseasesandthenutrientsthatregulate
their expressions to modify personal risks and to prevent,
mitigate, or treat diseases. Studying on an individual basis
the interactions between diet and genetics could help select
appropriatediettooptimizehealthstatus.Indeed,thepicture
becomes more complicated when lifestyle, behavioral, and
other environmental factors interfere with the diet-genetics
interaction.
Of note is the unique ethnic combination of the region’s
native populations that make studies from other regions
inapplicabletotheMENA.Inspiteofthemultiethnicorigins,
high rates of consanguinity in the subpopulations render
the genetic pool paradoxically limited and signiﬁcantly
increase not only the risk of congenital abnormalities but
also the susceptibility of the population to chronic diseases
and genetic disorders [167]. Screening for the common
polymorphisms in the MENA can give insights on their
prevalencein theregion orcanhelp discoverpolymorphisms
indigenous for the region. Such action could help alleviate
the burden of chronic diseases in the MENA simply by
suggesting adequate adjustments of dietary factors to hide a
genetic polymorphism or to prevent DNA damage.
In some of the examples provided previously, success can
be achieved, but in others, researchers ought to be more
cautious. Selecting which polymorphisms are to be screened
for, at the population level in the MENA, should be made
after careful understanding of the eﬀects of these variants on
diet and disease. This is crucial to avoid misleading results
and unnecessary costs. Unfortunately, functional studies are
limited,butwide-scalescreeningandassociationsfromother
regionsintheworldcouldguidethedecision-makingprocess
regarding screening in the MENA. At the same time, more
eﬀort and money should be invested in molecular and
cellular research in nutritional genomics in order to better
understand the function of the dietary signature and to more
conﬁdently guide population screening and personalized
diet.
8. Conclusions
(i) MENA countries are witnessing a radical change in
dietary patterns from a traditional diet to a less
healthy industrialized diet.
(ii) Rising prevalence for civilization diseases of metab-
olism and micronutrient deﬁciencies in the MENA
parallels the change in dietary habits and is mostly
caused by it.
(iii) Nutrigenomic factors and the dietary signature on
the genome play a role in the diet-disease interac-
tions.
(iv) Genetic sequence variations, epigenetic proﬁles, and
posttranscriptional and posttranslational modiﬁca-
tions are some of the mechanisms that deﬁne the
diet-genetics-disease relationship.
(v) A large set of gene polymorphisms have been corre-
lated with civilization diseases of metabolism, only a
little of which have been studied in MENA countries.
(vi) There are diﬀerent mechanisms through which diet-
genetics interaction aﬀects micronutrient pathways
and contributes to disease, including vitamin D and
calcium, iron, folate, and vitamins C and E.
(vii) Given the drastic dietary changes in the region over a
short period of time, diet is the most obvious public
health intervention, yet system biology and genomics
research should not be underestimated.
(viii) Wide-scale screening for certain gene polymor-
phisms in the MENA might allow for eﬃcient
intervention with personalized diet.
(ix) More nutrigenomics research is needed to look at
functionandmechanismsofthediet-genetics-disease
interaction.
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